Core Viewpoint - Niagen Bioscience, Inc. has expanded its NAD+ precursor intellectual property portfolio with the granting of U.S. Patent No. 12,558,367, which pertains to the use of nicotinamide riboside (NR) and its derivatives in intravenous and injectable formulations [1] Company Developments - The newly granted patent enhances the company's position as a leader in the NAD+ market, focusing on healthy aging [1] - CEO Rob Fried emphasized the significance of this patent in advancing the company's research and product development efforts [1]

Core Viewpoint - Niagen Bioscience, Inc. has acquired a comprehensive portfolio of patents related to nicotinamide riboside (NR) from Queen's University Belfast, enhancing its leadership in NAD+ precursor intellectual property [1] Group 1: Company Developments - The acquisition strengthens Niagen's long-standing ownership position in the NAD+ precursor market [1] - The focus of the company is on the science of healthy aging, positioning it as a global authority in NAD+ [1] Group 2: Industry Implications - The acquisition of these patents may lead to increased innovation and product development in the field of healthy aging and NAD+ research [1] - This move could potentially enhance the competitive landscape within the biotech industry, particularly in the area of aging-related health solutions [1]